获取途径

作者

Shuangmei Zhang Xiaodong Song An Rong Wang Zhaoxu Zhang

作者单位

³Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China ²Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China ⁵Department of Neurology, Peking University People's Hospital, Beijing, China ¹Department of Pain Rehabilitation, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China ⁴Department of Traditional Chinese Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China

刊名

Frontiers in Neurology

年份

2025

卷号

Vol.16

关键词

myasthenia gravis secukinumab IL-17 AChR Th17

摘要

BackgroundMyasthenia gravis is a chronic autoimmune disease caused by autoantibodies attacking the neuromuscular junction. Traditional treatments are often accompanied by side effects and lack specificity. Recent studies have found that Th17 cells and the inflammatory factor IL-17, which they secrete, play a key role in the pathogenesis of MG and have become potential therapeutic targets. Secukinumab, an IL-17 inhibitor, has shown efficacy in other autoimmune diseases, but its role in MG remain...更多

BackgroundMyasthenia gravis is a chronic autoimmune disease caused by autoantibodies attacking the neuromuscular junction. Traditional treatments are often accompanied by side effects and lack specificity. Recent studies have found that Th17 cells and the inflammatory factor IL-17, which they secrete, play a key role in the pathogenesis of MG and have become potential therapeutic targets. Secukinumab, an IL-17 inhibitor, has shown efficacy in other autoimmune diseases, but its role in MG remains unexplored.ObjectiveThis study aimed to evaluate the clinical efficacy and immunomodulatory effects of secukinumab in acetylcholine receptor antibody-positive generalized MG .MethodsIn this single-center retrospective study, 29 AChR+ gMG patients received subcutaneous secukinumab . Clinical outcomes , AChR antibody titers, Th17 cell frequency, and IL-17 levels were assessed at baseline and during treatment. Correlations between biomarkers and clinical improvements were analyzed.ResultsBy week 24, secukinumab treatment led to significant reductions in disease severity scores and AChR antibody levels . Th17 cell frequency and IL-17 levels decreased by 68 and 84.47%, respectively. Strong baseline correlations were observed between IL-17, Th17, and clinical scores , with progressive uncoupling of these relationships during treatment. No severe adverse events were reported.ConclusionSecukinumab demonstrated rapid and sustained clinical benefits in AChR+ gMG, linked to suppression of the Th17/IL-17 pathway. These findings highlight IL-17 inhibition as a promising targeted strategy for MG. Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.收起

文献类型

期刊

浏览量

9